Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Differential expression of a new isoform of DLG2 in renal oncocytoma

Authors: Dmitry Zubakov, Zorica Stupar, Gyula Kovacs

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Renal oncocytoma, a benign tumour of the kidney, may pose a differential diagnostic problem due to overlapping phenotype with chromophobe renal cell carcinoma or other types of renal cell tumours. Therefore, identification of molecular markers would be of great value for molecular diagnostics of this tumour type.

Methods

In the current study we applied various techniques, including Affymetrix microarray hybridization and semiquantitative RT-PCR, to identify genes expressed differentially in renal oncocytomas. Subsequently, we used RACE and Northern blot hybridization to characterize the potential candidates for molecular diagnosis.

Results

We have identified new isoform of DLG2 gene, which contains 3'-end exons of the known DLG2 gene along with the hypothetical gene FLJ37266. The new isoform is specifically upregulated in renal oncocytoma, whereas the known DLG2 gene is downregulated in this type of kidney tumour.

Conclusion

The new isoform of DLG2 is the promising candidate gene for molecular differential diagnostics of renal oncocytoma.
Appendix
Available only for authorised users
Literature
1.
Skinnider BF, Jones EC: Renal oncocytoma and chromophobe renal cell carcinoma. A comparison of colloidal iron staining and electron microscopy. Am J Clin Pathol. 1999, 111 (6): 796-803.CrossRefPubMed
2.
Tickoo SK, Amin MB, Zarbo RJ: Colloidal iron staining in renal epithelial neoplasms, including chromophobe renal cell carcinoma: emphasis on technique and patterns of staining. Am J Surg Pathol. 1998, 22 (4): 419-424. 10.1097/00000478-199804000-00005.CrossRefPubMed
3.
Koller A, Kain R, Haitel A, Mazal PR, Asboth F, Susani M: Renal oncocytoma with prominent intracytoplasmic vacuoles of mitochondrial origin. Histopathology. 2000, 37 (3): 264-268. 10.1046/j.1365-2559.2000.00950.x.CrossRefPubMed
4.
Kovacs G: Molecular differential pathology of renal cell tumours. Histopathology. 1993, 22 (1): 1-8.CrossRefPubMed
5.
Bugert P, Kovacs G: Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol. 1996, 149 (6): 2081-2088.PubMedPubMedCentral
6.
Nagy A, Buzogany I, Kovacs G: Microsatellite allelotyping differentiates chromophobe renal cell carcinomas from renal oncocytomas and identifies new genetic changes. Histopathology. 2004, 44 (6): 542-546. 10.1111/j.1365-2559.2004.01884.x.CrossRefPubMed
7.
Fuzesi L, Frank D, Nguyen C, Ringert R-H, Bartels H, Gunawan B: Losses of 1p and chromosome 14 in renal oncocytomas. Cancer Genet Cytogenet. 2005, 160 (2): 120-125. 10.1016/j.cancergencyto.2004.12.010.CrossRefPubMed
8.
Herbers J, Schullerus D, Chudek J, Bugert P, Kanamaru H, Zeisler J, Ljungberg B, Akhtar M, Kovacs G: Lack of genetic changes at specific genomic sites separates renal oncocytomas from renal cell carcinomas. J Pathol. 1998, 184 (1): 58-62. 10.1002/(SICI)1096-9896(199801)184:1<58::AID-PATH987>3.0.CO;2-1.CrossRefPubMed
9.
Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Presti JC, Kovacs G, Waldman FM: Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res. 2002, 62 (4): 957-960.PubMed
10.
Mete O, Kilicaslan I, Gulluoglu MG, Uysal V: Can renal oncocytoma be differentiated from its renal mimics? The utility of anti-mitochondrial, caveolin 1, CD63 and cytokeratin 14 antibodies in the differential diagnosis. Virchows Arch. 2005, 447 (6): 938-946. 10.1007/s00428-005-0048-6.CrossRefPubMed
11.
Pan C-C, Chen PC-H, Ho DM-T: The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology. 2004, 45 (5): 452-459. 10.1111/j.1365-2559.2004.01962.x.CrossRefPubMed
12.
Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, Laskin WB, Yeldandi A, Teh BT, Yang XJ: C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol. 2005, 36 (3): 262-268. 10.1016/j.humpath.2005.01.011.CrossRefPubMed
13.
Mazal PR, Exner M, Haitel A, Krieger S, Thomson RB, Aronson PS, Susani M: Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol. 2005, 36 (1): 22-28. 10.1016/j.humpath.2004.09.011.CrossRefPubMed
14.
Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, van den Berg E, Zbar B: The Heidelberg classification of renal cell tumours. J Pathol. 1997, 183 (2): 131-133. 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G.CrossRefPubMed
15.
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162 (1): 156-159. 10.1016/0003-2697(87)90021-2.CrossRefPubMed
16.
17.
18.
Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, Gray SG, Knapp R, Anema J, Kahnoski R, Nicol D, Vogelzang NJ, Furge KA, Kanayama H, Kagawa S, Teh BT: Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003, 22 (43): 6810-6818. 10.1038/sj.onc.1206869.CrossRefPubMed
19.
Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS: Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001, 158 (5): 1639-1651.CrossRefPubMedPubMedCentral
20.
Higgins JPT, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, Brooks JD: Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 2003, 162 (3): 925-932.CrossRefPubMedPubMedCentral
21.
Caruana G: Genetic studies define MAGUK proteins as regulators of epithelial cell polarity. Int J Dev Biol. 2002, 46 (4): 511-518.PubMed
22.
Kim E, Cho KO, Rothschild A, Sheng M: Heteromultimerization and NMDA receptor-clustering activity of Chapsyn-110, a member of the PSD-95 family of proteins. Neuron. 1996, 17 (1): 103-113. 10.1016/S0896-6273(00)80284-6.CrossRefPubMed
Metadata
Title
Differential expression of a new isoform of DLG2 in renal oncocytoma
Authors
Dmitry Zubakov
Zorica Stupar
Gyula Kovacs
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-106

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Local radiotherapeutic management of ependymomas with fractionated stereotactic radiotherapy (FSRT)

Research article

Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells

Research article

High Smac/DIABLO expression is associated with early local recurrence of cervical cancer

Research article

A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo

Research article

Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide

Research article

Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits